Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
SAN DIEGO, March 27, 2024 /PRNewswire/ -- The company behind Phexxi® (lactic acid, citric acid, and potassium bitartrate) vaginal gel, women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2023. Highlights include:
- Highlights include:
Delivered $18.2 million of Phexxi net product sales in 2023, an impressive increase compared to 2022 given the 73% reduction in field force and absence of growth capital in 2023. - Sales and marketing expense was 64% of net sales for 2023, a key milestone for the Company and a significant improvement from prior years.
- For the year ended December 31, 2023, net product sales were $18.2 million compared to $16.8 million in net product sales in the prior year.
- For the three months ended December 31, 2023, net product sales were $4.8 million compared to $0.2 million in the prior year period.